Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity

Fineline Cube Dec 19, 2025
Company Drug

Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo

Fineline Cube Dec 19, 2025
R&D

BGI’s Stereo-seq Tech Maps Axolotl Brain Regeneration in World-First Study

Fineline Cube Sep 5, 2022

China’s genomics giant BGI has revealed a landmark study using its proprietary Stereo-seq sequencing technology...

Company Drug

Yingli Pharma Doses First Patient in Linperlisib Phase II Trial for PTCL

Fineline Cube Sep 5, 2022

US-based Yingli Pharma, which targets the China and US drug markets, has dosed the first...

Company Deals

Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion

Fineline Cube Sep 5, 2022

China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up...

Company Drug

CanSino, Livzon Win China EUAs for COVID-19 Booster Vaccines

Fineline Cube Sep 5, 2022

China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have...

Company Deals Digital

AWS Partners with Zhongshan to Launch Smart Manufacturing and Biomedical Digital Center

Fineline Cube Sep 5, 2022

Amazon Web Services (AWS) and Zhongshan’s Bureau of Commerce announced a partnership at the China...

Company Deals

BoomRay Pharmaceuticals Raises USD 43M in Series A for RDC Pipeline Expansion

Fineline Cube Sep 5, 2022

China’s BoomRay Pharmaceuticals, a specialist in radionuclide drug conjugates (RDCs), reportedly raised nearly RMB 300...

Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Wins FDA Approval for Severe Alopecia Areata

Fineline Cube Sep 5, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) secured U.S. FDA approval to launch a clinical...

Company Drug

Jacobio Pharmaceuticals Doses First Patient in JAB-BX102 Phase I/IIa Trial for CD73-Targeted Cancer Therapy

Fineline Cube Sep 5, 2022

China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...

Company Deals Drug

Northeast Pharma Licenses MedAbome’s MAb11-22.1 for ADC and CAR-T Development

Fineline Cube Sep 5, 2022

China’s Northeast Pharmaceutical Co., Ltd (SHE: 000597) has signed a licensing agreement with U.S.-based MedAbome...

Company Drug

Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022

Fineline Cube Sep 5, 2022

China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates...

Company Drug

AstraZeneca’s Farxiga Wins China Approval for Chronic Kidney Disease

Fineline Cube Sep 5, 2022

UK pharma giant AstraZeneca (AZ, NASDAQ: AZN) announced a new approval for Farxiga (dapagliflozin), its...

Company Drug

Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial

Fineline Cube Sep 5, 2022

China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...

Company Drug

Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval

Fineline Cube Sep 5, 2022

China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...

Company Drug

Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines

Fineline Cube Sep 2, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has received clinical trial approvals from the National...

Company Deals

Medim Science Raises Funds for Macrophage-Targeting Biologics in Cancer Therapy

Fineline Cube Sep 2, 2022

Hangzhou-based Medim Science, China’s first pharma firm focused on macrophage-targeting biologics, has reportedly raised tens...

Drug Medical Device

China’s Pharmaceutical Industry Sees Revenue Decline Amid Export Shifts

Fineline Cube Sep 2, 2022

China’s pharmaceutical manufacturing sector reported a 1.8% year-on-year (YOY) revenue decline to RMB 1.6 trillion...

Company Deals

Tibet Duo Rui and Nanjing Heron Forge Pharmaceutical Collaboration in China

Fineline Cube Sep 2, 2022

China-based Tibet Duo Rui Pharmaceutical Co., Ltd and Nanjing Heron Pharmaceutical Science and Technology Co.,...

Company Drug

CARsgen Therapeutics Launches GMP Manufacturing for CAR-T Cell Therapies in North Carolina

Fineline Cube Sep 2, 2022

China’s CARsgen Therapeutics Holdings Ltd (HKG: 2171), a chimeric antigen receptor (CAR)-T cell specialist, has...

Company Deals

MegaRobo and Danaher Life Sciences Partner on Lab Automation in China

Fineline Cube Sep 2, 2022

Beijing-based MegaRobo Technologies, a robotics and AI firm in life sciences, has partnered with Danaher...

Company Drug

Hengrui Medicine’s HRG2101 Inhaler Wins NMPA Approval for IPF Clinical Trial

Fineline Cube Sep 2, 2022

China’s Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has received approval from the National Medical...

Posts pagination

1 … 562 563 564 … 599

Recent updates

  • Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
  • Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo
  • Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network
  • Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee
  • Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity

Company Drug

Neurodawn’s Y-4 Wins FDA Fast Track for First‑in‑Class Neuropathic Pain Combo

Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Others

Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.